The clinical significance of CD44v6 in malignant and benign primary bone tumors
CONCLUSION: CD44v6 is likely to play a role in the development of primary bone tumors and has the potential to serve as a diagnostic biomarker for bone cancer. However, to obtain more accurate and conclusive findings, further mechanistic investigations involving larger population samples are necessary.PMID:37491225 | DOI:10.1186/s12891-023-06738-7 (Source: Cancer Control)
Source: Cancer Control - July 25, 2023 Category: Cancer & Oncology Authors: Ameinh Hosseini Amir Reza Eghtedari Alireza Mirzaei Pegah Babaheidarian Samira Nekoufar Narges Khademian Khodamorad Jamshidi Masoumeh Tavakoli-Yaraki Source Type: research
Protective Effects of a Mixed Medicinal Herb Extract (NUC1) on Collagenase-Induced Osteoarthritis in Rabbits
This study investigated the therapeutic effects of NUC1 on osteoarthritis (OA). The protective effect of NUC1 on OA was tested in a rabbit model of collagenase-induced arthritis (CIA) for 4 weeks. Results were compared among four groups (n = 9 per group): the normal group (untreated), the CIA group (vehicle control), the NUC1 group (CIA rabbits treated with 200 mg/kg NUC1), and the JOINS group (positive control, CIA rabbits treated with 200 mg/kg JOINS tablet). NUC1 significantly inhibited NO production (p < 0.05 at 125 μg/mL, p < 0.01 at 250 μg/mL, and p < 0.001 at 500 μg/mL) and iNOS expression in macrophages...
Source: Journal of Microbiology and Biotechnology - July 24, 2023 Category: Biotechnology Authors: Sung-Gyu Lee Hyun Kang Source Type: research
Protective Effects of a Mixed Medicinal Herb Extract (NUC1) on Collagenase-Induced Osteoarthritis in Rabbits
This study investigated the therapeutic effects of NUC1 on osteoarthritis (OA). The protective effect of NUC1 on OA was tested in a rabbit model of collagenase-induced arthritis (CIA) for 4 weeks. Results were compared among four groups (n = 9 per group): the normal group (untreated), the CIA group (vehicle control), the NUC1 group (CIA rabbits treated with 200 mg/kg NUC1), and the JOINS group (positive control, CIA rabbits treated with 200 mg/kg JOINS tablet). NUC1 significantly inhibited NO production (p < 0.05 at 125 μg/mL, p < 0.01 at 250 μg/mL, and p < 0.001 at 500 μg/mL) and iNOS expression in macrophages...
Source: Journal of Microbiology and Biotechnology - July 24, 2023 Category: Biotechnology Authors: Sung-Gyu Lee Hyun Kang Source Type: research
Protective Effects of a Mixed Medicinal Herb Extract (NUC1) on Collagenase-Induced Osteoarthritis in Rabbits
This study investigated the therapeutic effects of NUC1 on osteoarthritis (OA). The protective effect of NUC1 on OA was tested in a rabbit model of collagenase-induced arthritis (CIA) for 4 weeks. Results were compared among four groups (n = 9 per group): the normal group (untreated), the CIA group (vehicle control), the NUC1 group (CIA rabbits treated with 200 mg/kg NUC1), and the JOINS group (positive control, CIA rabbits treated with 200 mg/kg JOINS tablet). NUC1 significantly inhibited NO production (p < 0.05 at 125 μg/mL, p < 0.01 at 250 μg/mL, and p < 0.001 at 500 μg/mL) and iNOS expression in macrophages...
Source: Journal of Microbiology and Biotechnology - July 24, 2023 Category: Biotechnology Authors: Sung-Gyu Lee Hyun Kang Source Type: research
Protective Effects of a Mixed Medicinal Herb Extract (NUC1) on Collagenase-Induced Osteoarthritis in Rabbits
This study investigated the therapeutic effects of NUC1 on osteoarthritis (OA). The protective effect of NUC1 on OA was tested in a rabbit model of collagenase-induced arthritis (CIA) for 4 weeks. Results were compared among four groups (n = 9 per group): the normal group (untreated), the CIA group (vehicle control), the NUC1 group (CIA rabbits treated with 200 mg/kg NUC1), and the JOINS group (positive control, CIA rabbits treated with 200 mg/kg JOINS tablet). NUC1 significantly inhibited NO production (p < 0.05 at 125 μg/mL, p < 0.01 at 250 μg/mL, and p < 0.001 at 500 μg/mL) and iNOS expression in macrophages...
Source: Journal of Microbiology and Biotechnology - July 24, 2023 Category: Biotechnology Authors: Sung-Gyu Lee Hyun Kang Source Type: research
GANT-61 induces cell cycle resting and autophagy by down-regulating RNAP III signal pathway and tRNA-Gly-CCC synthesis to combate chondrosarcoma
Cell Death & Disease, Published online: 24 July 2023; doi:10.1038/s41419-023-05926-6GANT-61 induces cell cycle resting and autophagy by down-regulating RNAP III signal pathway and tRNA-Gly-CCC synthesis to combate chondrosarcoma (Source: Cell death and disease)
Source: Cell death and disease - July 24, 2023 Category: Internal Medicine Authors: Yifeng Sun Qiongxuan Fang Wei Liu Yi Liu Chunming Zhang Source Type: research
An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia
CONCLUSION: A conservative estimate is that 1% of cancer patients in Australia (or 2% of patients recommended for radiation therapy) may preferentially benefit from CIRT for initial therapy of radiation resistant tumours, or to boost persistently active disease after other therapies, or for re-irradiation of recurrent disease. On this basis, one national carbon ion facility with up to four treatment rooms is justified for Australian patients.PMID:37480996 | DOI:10.1016/j.radonc.2023.109816 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - July 22, 2023 Category: Radiology Authors: Verity Ahern Sebastian Adeberg Piero Fossati Richard Garrett Bradford Hoppe Anita Mahajan Ester Orlandi Roberto Orecchia Dale Prokopovich Jan Seuntjens David Thwaites Daniel Trifiletti Richard Tsang Hiroshi Tsuji Source Type: research
An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia
CONCLUSION: A conservative estimate is that 1% of cancer patients in Australia (or 2% of patients recommended for radiation therapy) may preferentially benefit from CIRT for initial therapy of radiation resistant tumours, or to boost persistently active disease after other therapies, or for re-irradiation of recurrent disease. On this basis, one national carbon ion facility with up to four treatment rooms is justified for Australian patients.PMID:37480996 | DOI:10.1016/j.radonc.2023.109816 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - July 22, 2023 Category: Radiology Authors: Verity Ahern Sebastian Adeberg Piero Fossati Richard Garrett Bradford Hoppe Anita Mahajan Ester Orlandi Roberto Orecchia Dale Prokopovich Jan Seuntjens David Thwaites Daniel Trifiletti Richard Tsang Hiroshi Tsuji Source Type: research
An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia
CONCLUSION: A conservative estimate is that 1% of cancer patients in Australia (or 2% of patients recommended for radiation therapy) may preferentially benefit from CIRT for initial therapy of radiation resistant tumours, or to boost persistently active disease after other therapies, or for re-irradiation of recurrent disease. On this basis, one national carbon ion facility with up to four treatment rooms is justified for Australian patients.PMID:37480996 | DOI:10.1016/j.radonc.2023.109816 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - July 22, 2023 Category: Radiology Authors: Verity Ahern Sebastian Adeberg Piero Fossati Richard Garrett Bradford Hoppe Anita Mahajan Ester Orlandi Roberto Orecchia Dale Prokopovich Jan Seuntjens David Thwaites Daniel Trifiletti Richard Tsang Hiroshi Tsuji Source Type: research
An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia
CONCLUSION: A conservative estimate is that 1% of cancer patients in Australia (or 2% of patients recommended for radiation therapy) may preferentially benefit from CIRT for initial therapy of radiation resistant tumours, or to boost persistently active disease after other therapies, or for re-irradiation of recurrent disease. On this basis, one national carbon ion facility with up to four treatment rooms is justified for Australian patients.PMID:37480996 | DOI:10.1016/j.radonc.2023.109816 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - July 22, 2023 Category: Radiology Authors: Verity Ahern Sebastian Adeberg Piero Fossati Richard Garrett Bradford Hoppe Anita Mahajan Ester Orlandi Roberto Orecchia Dale Prokopovich Jan Seuntjens David Thwaites Daniel Trifiletti Richard Tsang Hiroshi Tsuji Source Type: research
PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications
AbstractPreferentially expressed antigen in melanoma (PRAME) immunohistochemistry is currently used in pathology for the assessment of melanocytic neoplasms; however, knowledge of its expression patterns in soft tissue tumors is limited. PRAME immunohistochemistry (clone QR005) was assessed on whole tissue sections of 350 soft-tissue tumors and mimics (> 50 histotypes). PRAME immunoreactivity was evaluated as follows: 0 “negative” (0% positive cells); 1+ (1–25% positive cells); 2+ (26–50% positive cells); 3+ (51–75% positive cells), and 4+ “diffuse” (> 75% positive cells). PRAME was expressed in 111 les...
Source: Virchows Archiv - July 21, 2023 Category: Pathology Source Type: research
Mesenchymal Chondrosarcoma in the Mandible: A Case Report
(Source: Journal of Maxillofacial and Oral Surgery)
Source: Journal of Maxillofacial and Oral Surgery - July 20, 2023 Category: ENT & OMF Source Type: research
Malignant Brain and Spinal Tumors Originating from Bone or Cartilage
Adv Exp Med Biol. 2023;1405:477-506. doi: 10.1007/978-3-031-23705-8_18.ABSTRACTMalignant bone tumors affecting the brain and spine are a rare and exceedingly difficult-to-treat group of diseases. Most commonly consisting of chordoma and chondrosarcoma, these tumors also include giant-cell tumors and osteosarcomas. This chapter will cover the background, epidemiology, genetics, molecular biology, histopathology, radiographic features, clinical manifestations, therapeutic approaches, and clinical management of each entity.PMID:37452950 | DOI:10.1007/978-3-031-23705-8_18 (Source: Advances in Experimental Medicine and Biology)
Source: Advances in Experimental Medicine and Biology - July 15, 2023 Category: Research Authors: Zachary C Gersey Georgios A Zenonos Paul A Gardner Source Type: research
